Skip to main content

Table 5 Excess mortality according to CD4 cell count and plasma HIV-1 RNA category among HIV-1 infected participants, after adjusting for ART use

From: Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: Results of analyses from a multicenter randomized trial

 

Incidence ofmedical death

Estimated excess mortality per 1000 person-years (95% CI)

P-value

Number needed to treat per year (95% CI) to avert 1 death

HIV-1 uninfected

3.6

Reference

-

Reference

HIV-1 infected

13.7

10.2 (6.9, 13.5)

<.001

 

CD4 cell count

    

  ≥500

4.8

1.2 (−1.8, 4.2)

.44

851

  350-499

13.1

8.9 (3.8, 14.0)

<.001

113

  250-349

19.9

15.2 (8.1, 22.2)

<.001

66

  <250

42.7

29.3 (13.9, 44.7)

<.001

34

HIV-1 RNA

    

  HIV-1 <10 K

7.7

2.0 (−1.1, 5.0)

.21

509

  10 K-50 K

3.7

−0.6 (−3.4, 2.3)

.69

NA

  50 K-100 K

13.9

6.7 (−0.6, 14.0)

.071

149

  >100 K

46.9

43.0† (29.6, 56.4)

<.001

23

  1. † An interaction term was also present in the model between high HIV viral load and use of ART (p = .002). The excess mortality in the last row applies to those not on ART. For those on ART, mortality was not found to exceed that of HIV-1 uninfected (p = 0.58).